Annual Lung SPORE Workshop (Abstract Submission): Submission #10

Submission information
Submission Number: 10
Submission ID: 110371
Submission UUID: 7e633443-a6ca-4268-b138-1d82ec367fe5

Created: Fri, 03/08/2024 - 18:05
Completed: Fri, 03/08/2024 - 18:16
Changed: Wed, 05/29/2024 - 17:10

Remote IP address: 10.208.28.228
Submitted by: Anonymous
Language: English

Is draft: No
Monique (Presented by Heymach)
Nilsson
7137458407
MD Anderson Cancer Center - John Heymach
Trastuzumab deruxtecan resistance can be mediated by payload resistance or secondary extracellular ERBB2 mutations but sensitivity to HER2 tyrosine kinase inhibitors is maintained
First Author
John
Heymach (Submitted by M. Nilsson)
MD Anderson Cancer Center
Additional Authors
  • First Name: Xiuning
    Last Name: Le
    Affiliation: MDACC
  • First Name: Junqin
    Last Name: He
    Affiliation: MDACC
  • First Name: Xiaoxing
    Last Name: Yu
    Affiliation: MDACC
  • First Name: Xiaofang
    Last Name: Huo
    Affiliation: UTSW
  • First Name: Ashwani
    Last Name: Kumar
    Affiliation: UTSW
  • First Name: Alissa
    Last Name: Poteete
    Affiliation: MDACC
  • First Name: Qian
    Last Name: Huang
    Affiliation: MDACC
  • First Name: Ralf
    Last Name: Kittler
    Affiliation: UTSW
  • First Name: John
    Last Name: Heymach
    Affiliation: MDACC
Session 1: Oncogene-driven lung cancers and resistance to targeted therapies
No
{Empty}
{Empty}
Poster Submission
2024.5.29 Heymach Lung Spore Enhertu Resistance.jpg